{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T23:03:19Z","timestamp":1776207799754,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Brainlab Inc.","award":["2020-KOT-004"],"award-info":[{"award-number":["2020-KOT-004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s11060-025-05038-5","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T10:00:13Z","timestamp":1745316013000},"page":"121-129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrating a novel tablet-based digital neurocognitive assessment tool in brain metastases patients"],"prefix":"10.1007","volume":"174","author":[{"given":"Eyub Y.","family":"Akdemir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selin","family":"Gurdikyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thailin Companioni","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazmin","family":"Odia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A. Ramirez","family":"Menendez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreenija","family":"Yarlagadda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer","family":"Gal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert H.","family":"Press","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Jay","family":"Wieczorek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongsook C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjini","family":"Tolakanahalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alonso N.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manmeet S.","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minesh P.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupesh","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"issue":"1","key":"5038_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1200\/JCO.2004.05.128","volume":"22","author":"CA Meyers","year":"2004","unstructured":"Meyers CA, Smith JA, Bezjak A et al (2004) Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22(1):157\u2013165","journal-title":"J Clin Oncol"},{"issue":"2","key":"5038_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1227\/01.NEU.0000249272.64439.B1","volume":"60","author":"EL Chang","year":"2007","unstructured":"Chang EL, Wefel JS, Maor MH et al (2007) A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 60(2):277\u2013283 discussion 283\u2013\u2009274","journal-title":"Neurosurgery"},{"issue":"6","key":"5038_CR3","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/CCO.0000000000000581","volume":"31","author":"MB Coomans","year":"2019","unstructured":"Coomans MB, van der Linden SD, Gehring K, Taphoorn MJB (2019) Treatment of cognitive deficits in brain tumour patients: current status and future directions. Curr Opin Oncol 31(6):540\u2013547","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"5038_CR4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/arclin\/acx131","volume":"33","author":"KR Noll","year":"2018","unstructured":"Noll KR, Bradshaw ME, Rexer J, Wefel JS (2018) Neuropsychological practice in the oncology setting. Arch Clin Neuropsychol 33(3):344\u2013353","journal-title":"Arch Clin Neuropsychol"},{"issue":"8","key":"5038_CR5","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","volume":"18","author":"PD Brown","year":"2017","unstructured":"Brown PD, Ballman KV, Cerhan JH et al (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1049\u20131060","journal-title":"Lancet Oncol"},{"issue":"11","key":"5038_CR6","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","volume":"10","author":"EL Chang","year":"2009","unstructured":"Chang EL, Wefel JS, Hess KR et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10(11):1037\u20131044","journal-title":"Lancet Oncol"},{"key":"5038_CR7","doi-asserted-by":"publisher","first-page":"893264","DOI":"10.3389\/fonc.2022.893264","volume":"12","author":"EJ Lehrer","year":"2022","unstructured":"Lehrer EJ, Jones BM, Dickstein DR et al (2022) The cognitive effects of radiotherapy for brain metastases. Front Oncol 12:893264","journal-title":"Front Oncol"},{"issue":"1","key":"5038_CR8","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/s41598-022-05682-1","volume":"12","author":"AL Whittaker","year":"2022","unstructured":"Whittaker AL, George RP, O\u2019Malley L (2022) Prevalence of cognitive impairment following chemotherapy treatment for breast cancer: a systematic review and meta-analysis. Sci Rep 12(1):2135","journal-title":"Sci Rep"},{"issue":"11","key":"5038_CR9","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1002\/cncr.20272","volume":"100","author":"JS Wefel","year":"2004","unstructured":"Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100(11):2292\u20132299","journal-title":"Cancer"},{"issue":"10","key":"5038_CR10","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1016\/S1470-2045(13)70308-5","volume":"14","author":"NU Lin","year":"2013","unstructured":"Lin NU, Wefel JS, Lee EQ et al (2013) Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol 14(10):e407\u2013416","journal-title":"Lancet Oncol"},{"issue":"4","key":"5038_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","volume":"316","author":"PD Brown","year":"2016","unstructured":"Brown PD, Jaeckle K, Ballman KV et al (2016) Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial. JAMA 316(4):401\u2013409","journal-title":"JAMA"},{"issue":"2","key":"5038_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","volume":"29","author":"M Kocher","year":"2011","unstructured":"Kocher M, Soffietti R, Abacioglu U et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952\u201326001 study. J Clin Oncol 29(2):134\u2013141","journal-title":"J Clin Oncol"},{"issue":"2","key":"5038_CR13","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/j.ijrobp.2023.06.1115","volume":"117","author":"BC Adegboyega","year":"2023","unstructured":"Adegboyega BC, Joseph AO, Alabi OA et al (2023) Patient reported outcomes following palliative whole brain radiation therapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys 117(2):e217\u2013e218","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"5038_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijrobp.2023.04.030","volume":"117","author":"V Gondi","year":"2023","unstructured":"Gondi V, Deshmukh S, Brown PD et al (2023) Sustained preservation of cognition and prevention of Patient-Reported symptoms with hippocampal avoidance during Whole-Brain radiation therapy for brain metastases: final results of NRG oncology CC001. Int J Radiat Oncol Biol Phys 117(3):571\u2013580","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"5038_CR15","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.21037\/apm-21-1545","volume":"11","author":"D Hartgerink","year":"2022","unstructured":"Hartgerink D, Bruynzeel A, Eekers D et al (2022) Quality of life among patients with 4 to 10 brain metastases after treatment with whole-brain radiotherapy vs. stereotactic radiotherapy: a phase III, randomized, Dutch multicenter trial. Ann Palliat Med 11(4):1197\u20131209","journal-title":"Ann Palliat Med"},{"issue":"12","key":"5038_CR16","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1001\/jamaoncol.2022.5049","volume":"8","author":"JD Palmer","year":"2022","unstructured":"Palmer JD, Klamer BG, Ballman KV et al (2022) Association of Long-term outcomes with stereotactic radiosurgery vs Whole-Brain radiotherapy for resected brain metastasis: A secondary analysis of the N107C\/CEC.3 (Alliance for clinical trials in Oncology\/Canadian cancer trials Group) randomized clinical trial. JAMA Oncol 8(12):1809\u20131815","journal-title":"JAMA Oncol"},{"issue":"7","key":"5038_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S1470-2045(10)70294-1","volume":"12","author":"JS Wefel","year":"2011","unstructured":"Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12(7):703\u2013708","journal-title":"Lancet Oncol"},{"issue":"6","key":"5038_CR18","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.jpainsymman.2015.06.019","volume":"50","author":"F Joly","year":"2015","unstructured":"Joly F, Giffard B, Rigal O et al (2015) Impact of cancer and its treatments on cognitive function: advances in research from the Paris international cognition and cancer task force symposium and update since 2012. J Pain Symptom Manage 50(6):830\u2013841","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"5038_CR19","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/neuonc\/nov186","volume":"18","author":"EJ Habets","year":"2016","unstructured":"Habets EJ, Dirven L, Wiggenraad RG et al (2016) Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study. Neuro Oncol 18(3):435\u2013444","journal-title":"Neuro Oncol"},{"issue":"5","key":"5038_CR20","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.clon.2021.01.003","volume":"33","author":"WCM Schimmel","year":"2021","unstructured":"Schimmel WCM, Verhaak E, Bakker M, Hanssens PEJ, Sitskoorn MM, Gehring K (2021) Group and individual change in cognitive functioning in patients with 1 to 10 brain metastases following gamma knife radiosurgery. Clin Oncol (R Coll Radiol) 33(5):314\u2013321","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"5","key":"5038_CR21","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1586\/era.12.34","volume":"12","author":"C Caine","year":"2012","unstructured":"Caine C, Mehta MP, Laack NN, Gondi V (2012) Cognitive function testing in adult brain tumor trials: lessons from a comprehensive review. Expert Rev Anticancer Ther 12(5):655\u2013667","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"5038_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s11060-014-1550-y","volume":"120","author":"S Onodera","year":"2014","unstructured":"Onodera S, Aoyama H, Tha KK et al (2014) The value of 4-month neurocognitive function as an endpoint in brain metastases trials. J Neurooncol 120(2):311\u2013319","journal-title":"J Neurooncol"},{"key":"5038_CR23","unstructured":"WHO guideline: recommendations on digital interventions for health system strengthening. Geneva: World Health Organization (2019) 2019"},{"issue":"2","key":"5038_CR24","doi-asserted-by":"publisher","first-page":"e032733","DOI":"10.1161\/JAHA.123.032733","volume":"13","author":"I De Anda-Duran","year":"2024","unstructured":"De Anda-Duran I, Sunderaraman P, Searls E et al (2024) Comparing cognitive tests and Smartphone-Based assessment in 2 US Community-Based cohorts. J Am Heart Assoc 13(2):e032733","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"5038_CR25","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s41597-022-01872-8","volume":"9","author":"PI Jaffe","year":"2022","unstructured":"Jaffe PI, Kaluszka A, Ng NF, Schafer RJ (2022) A massive dataset of the neurocognitive performance test, a web-based cognitive assessment. Sci Data 9(1):758","journal-title":"Sci Data"},{"issue":"6","key":"5038_CR26","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.3171\/2022.3.FOCUS21726","volume":"52","author":"VM Butenschoen","year":"2022","unstructured":"Butenschoen VM, Ahlfeld J, Meyer B, Krieg SM (2022) Digital cognitive testing using a tablet-based app in patients with brain tumors: a single-center feasibility study comparing the app to the gold standard. Neurosurg Focus 52(6):E7","journal-title":"Neurosurg Focus"},{"issue":"1","key":"5038_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s13760-021-01744-9","volume":"122","author":"K Leemans","year":"2022","unstructured":"Leemans K, De Ridder M (2022) Cognition: development of a cognitive testing battery on the iPad for the evaluation of patients with brain Mets. Acta Neurol Belg 122(1):145\u2013152","journal-title":"Acta Neurol Belg"},{"issue":"2","key":"5038_CR28","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s11764-022-01232-w","volume":"18","author":"AM Gaynor","year":"2024","unstructured":"Gaynor AM, Ahsan A, Jung D et al (2024) Novel computerized neurocognitive test battery is sensitive to cancer-related cognitive deficits in survivors. J Cancer Surviv 18(2):466\u2013478","journal-title":"J Cancer Surviv"},{"issue":"3","key":"5038_CR29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/arclin\/acr120","volume":"27","author":"K Duff","year":"2012","unstructured":"Duff K (2012) Evidence-based indicators of neuropsychological change in the individual patient: relevant concepts and methods. Arch Clin Neuropsychol 27(3):248\u2013261","journal-title":"Arch Clin Neuropsychol"},{"issue":"1","key":"5038_CR30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/arclin\/acq084","volume":"26","author":"AD Hinton-Bayre","year":"2010","unstructured":"Hinton-Bayre AD (2010) Calculating the Test-Retest reliability Co-efficient from normative retest data for determining reliable change. Arch Clin Neuropsychol 26(1):76\u201377","journal-title":"Arch Clin Neuropsychol"},{"issue":"2","key":"5038_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/arclin\/16.2.183","volume":"16","author":"GL Iverson","year":"2001","unstructured":"Iverson GL (2001) Interpreting change on the WAIS-III\/WMS-III in clinical samples. Arch Clin Neuropsychol 16(2):183\u2013191","journal-title":"Arch Clin Neuropsychol"},{"issue":"1","key":"5038_CR32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1037\/0894-4105.10.1.120","volume":"10","author":"LJ Ingraham","year":"1996","unstructured":"Ingraham LJ, Aiken CB (1996) An empirical approach to determining criteria for abnormality in test batteries with multiple measures. Neuropsychology 10(1):120\u2013124","journal-title":"Neuropsychology"},{"issue":"3","key":"5038_CR33","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ijrobp.2018.02.160","volume":"104","author":"R Kotecha","year":"2019","unstructured":"Kotecha R, Mehta MP (2019) The complexity of managing large brain metastasis. Int J Radiat Oncol Biol Phys 104(3):483\u2013484","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5038_CR34","first-page":"100664","volume":"42","author":"CML Zegers","year":"2023","unstructured":"Zegers CML, Offermann C, Dijkstra J et al (2023) Clinical implementation of standardized neurocognitive assessment before and after radiation to the brain. Clin Transl Radiat Oncol 42:100664","journal-title":"Clin Transl Radiat Oncol"},{"issue":"12","key":"5038_CR35","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/neuonc\/noaa192","volume":"22","author":"MT Milano","year":"2020","unstructured":"Milano MT, Chiang VLS, Soltys SG et al (2020) Executive summary from American radium society\u2019s appropriate use criteria on neurocognition after stereotactic radiosurgery for multiple brain metastases. Neuro Oncol 22(12):1728\u20131741","journal-title":"Neuro Oncol"},{"key":"5038_CR36","unstructured":"Center PR (2023) Latinos in the U.S.| Data on U.S. Hispanics"},{"issue":"3","key":"5038_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/13803395.2017.1339017","volume":"40","author":"HEM Feenstra","year":"2018","unstructured":"Feenstra HEM, Murre JMJ, Vermeulen IE, Kieffer JM, Schagen SB (2018) Reliability and validity of a self-administered tool for online neuropsychological testing: the Amsterdam cognition scan. J Clin Exp Neuropsychol 40(3):253\u2013273","journal-title":"J Clin Exp Neuropsychol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05038-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05038-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05038-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T13:13:28Z","timestamp":1750857208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05038-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["5038"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05038-5","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EYA: None. SG: None.TCR: None.Y.O: Consulting fees from Istari Oncology, PharPoint Research; Participation on a Data Safety Monitoring Board or Advisory Board in Actuate, GammaTile, Novocure; other financial or non-financial interests in Blue Earth Diagnostics, BMS, Cantex Pharmaceuticals, Chimerix, CNS Pharmaceuticals, Exelixis, Karyopharm, MimiVax LLC, VBI Vaccines. MRM: None.SY: None.OG: None.M.D.H: Grant support from Florida Department of Health, Grant 22L01. Proton Therapy Cooperative Group of North America (PTCOG-NA) Treasurer (unpaid); Proton Therapy Cooperative Group (PTCOG) Pediatric Subcommittee Co-Chair (unpaid); Proton Collaborative Group (PCG) Executive Council Representative for Miami Cancer Institute (unpaid). RHP: None.DJW: None.CL: None.RT: None.ANG: Honoraria from ViewRay, Inc., Elekta AB, IBA; Ownership interest of Atlantic Health Solutions (uPlan), LLC.MWM: Consultant Deinde Medical and Stryker Medical.MSA: Grants from Seagen, AstraZeneca, BMS, Bayer, Incyte, Pharmacyclics, Novocure, MimiVax, and Merck; consulting fees from Bayer, Novocure, Kiyatec, Insightec, GSK, Xoft, Nuvation, Celularity, SDP Oncology, Apollomics, Prelude Therapeutics, Janssen, Tocagen, Voyager Therapeutics, ViewRay, Caris Life Sciences, Pyramid Biosciences, Varian Medical Systems, Cairn Therapeutics, AnHeart Therapeutics, Menarini Ricerche, Sumitomo Pharma Oncology, Autem therapeutics, GT Medical Technologies, Allovir, Equillium Bio., QV Bioelectronics, and Theraguix; scientific advisory board memberships for Cairn Therapeutics, Pyramid Biosciences, Bugworks, and Modifi Biosciences; data safety and monitoring committee membership for VBI Vaccines; stock shareholder in MimiVax, CytoDyn, Trisalus Lifesciences, and MedInnovate Advisors, LLC.M.P.M.: Consulting Fees from Telix, Zap, Xoft, Kazia Therapeutics, Novocure; Mevion Technological Advisory Board; NRG Brain Tumor Committee Chair; Leadership (unpaid) Board of Directors, Xcision; Stock in Chimerix.R.K.: Honoraria from Elekta AB, Accuray Inc., Novocure Inc., ViewRay Inc., Elsevier Inc., Brainlab, Peerview Institute for Medical Education, and Ion Beam Applications; consulting fees from Kazia Therapeutics, Elekta AB, ViewRay Inc., Castle Biosciences, Novocure Inc.; institutional research funding from Medtronic Inc., Blue Earth Diagnostics Ltd., Novocure Inc., GT Medical Technologies, AstraZeneca, Exelixis, ViewRay Inc., Brainlab, Cantex Pharmaceuticals, Kazia Therapeutics and Ion Beam Applications; support for travel or meeting attendance by Elekta AB, Accuray Inc., Novocure Inc., Peerview Institute for Medical Education, Brainlab, ViewRay Inc.; and participation on an advisory board for Viewray Medical Advisory Board, GT Medical Technologies Data Safety Monitoring Board, Insightec Ltd, Plus Therapeutics, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}